TrialPath
← Back to searchRecruiting

Clinical Applications of Advanced Ophthalmic Imaging

NCT03135327 · University of Miami
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study
The purpose of this study is to determine the clinical application of advanced ophthalmic imaging devices such as optical coherence tomography (OCT), retinal function imager (RFI), slit-lamp biomicroscopy (SLB), PERG in diseased eyes and normal controls. There are two phases in this study. The first phase is an observational phase which studies the eye in various conditions. The second phase is an interventional phase which studies the changes in the eyes after taking an over-the-counter medical food (Ocufolin) for 6 months.
Eligibility criteria
Observational Phase 1 Group Inclusion Criteria: 1. Self-reported normal healthy subjects; 2. Clinical diagnosis of Alzheimer's Disease, mild cognitive impairment, multiple sclerosis, dry eye, myopia, diabetics and stroke; 3. Who can keep the eye open for imaging. Exclusion Criteria: 1. who can not read and sign the ICF; 2. who can not receiving ophthalmic imaging; 3. who cannot tolerate bright light during imaging. Interventional Phase 2 Group: Inclusion criteria The participant will be eligible for entry in the study if s/he: 1. Is at least 18 years old and has full legal capacity to volunteer; 2. Has read and signed the IRB Informed Consent Document; 3. Is willing and able to follow participant instructions; 4. Has clear corneas and crystalline lens; 5. Initial visual acuities were 20/80 or better; 6. MTHFR C677TT homozygous, or MTHFR C677T/A1298C compound heterozygous with mild to moderate micro-aneurismal vascular retinopathy disease; 7. Hemoglobin A1c is 10 or less; 8. Normotensive with or without medications; 9. Without retinal capillary dropout or macular edema; 10. Blood homocysteine \> 9. Exclusion criteria The subjects will be ineligible for entry into the study if s/he: 1. Has an active ocular disease; 2. Has had surgery or an eye injury within 6 months.
Study design
Enrollment target: 5000 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2007-01-01
Estimated completion: 2029-12-31
Last updated: 2025-08-12
Interventions
Dietary Supplement: Ocufolin
Primary outcomes
  • Retinal microstructure using OCT. (up to 2 years)
  • Retinal vasculature by optical coherence tomography angiography (OCTA) (up to 2 years)
  • Conjunctival vasculature by functional slit-lamp (FSLB) (up to 2 years)
Sponsor
University of Miami · other
Contacts & investigators
ContactJianhua Wang, MD, PhD · contact · jwang3@med.miami.edu · 3054825010
InvestigatorJianhua Wang, MD, PhD · principal_investigator, Bascom Palmer Eye Institute, University of Miami, Miami, FL
All locations (1)
Bascom Palmer Eye InstituteRecruiting
Miami, Florida, United States